N/A N=252 Collaborative Perinatal Mental Health and Parenting Support in Primary Care
Parenting · Mother-child Relations
Primary: Change in Parent Sensitivity in Teaching — 36.73; 35.32 score on a scale — p=.026
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=116 Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)
Safety and Tolerability · Compare SHINGRIX Vaccine Response Rates · Chronic Lymphocytic Leukemia (CLL)
Primary: Number of Participants With Varicella Zoster Virus (VZV) Seroprotective Titer — 43; 11; 9 Participants
Phase 4 N=801 Etomidate Versus Ketamine for Emergency Endotracheal Intubation: a Prospective Randomized Clinical Trial
Cardiopulmonary Arrest · Respiratory Arrest
Primary: Survival at Day 7 — 306; 336 Participants
Phase 4 N=81 1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients
Brain Neoplasms · Brain Cancer · Brain Tumors
Primary: Change in Neurotoxicity Scale Scores — -1; -3.5 score on scale — p=0.7824
Phase 2 N=30 Topical Capsaicin for Cyclical Vomiting
Cyclical Vomiting
Primary: Nausea Visual Analog Scale — 41; 61 mm
Phase 3 N=47 Participant Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris
Acne Vulgaris
Primary: Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 12 and 24 — -1.8; -0.5 score on a scale
Phase 2 N=78 HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)
Hepatitis · Safety and Tolerability
Primary: Number of Participants With HEPLISAV-B Seroprotective Titer (Anti-HBs 10mIU/mL) — 0; 1; 9 Participants
N/A N=38 Histologic Comparison of Healing After Tooth Extraction With Ridge Preservation Using Two Different Xenografts
Partial Edentulism
Primary: New Bone Formation at Extraction/Xenograft Site Measured by Histological Evaluation at 16-20 Weeks — 29.38; 32.05; 14.02; 16.56 Percent
Phase 4 N=5 Simvastatin for mTBI
TBI-Traumatic Brain Injury
Primary: Cerebrospinal Fluid (CSF) T-tau Concentration — 24; 33.5 pg/ml
Phase 3 N=388 PALISADE Follow-on Study (ARC004)
Peanut Allergy
Primary: Percentage of Subjects Ages 4-17 With Treatment-related Adverse Events (TEAE) — 98; 90; 36; 27 Participants
Phase 4 N=2 Tissue Sealant Use in LASIK Enhancement Surgery
Epithelial Ingrowth
Primary: Slit Lamp Examination for Presence of Epithelial Ingrowth Under LASIK Flap — 0 Eyes
Phase 3 N=262 Cantharidin Application in Molluscum Patients
Molluscum Contagiosum
Primary: Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 84 Visit (EOS) — 81; 15 Participants
Phase 3 N=118 Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)
Conjunctivitis, Vernal
Primary: Overall Rating of Subjective Symptoms of VKC in Period I — 7; 1; 4; 5 Participants — p=0.2699
N/A N=81 Thumb vs Great Toe Recovery
Residual Neuromuscular Blockade
Primary: Onset Time of Muscle Relaxation for Flexor Hallucis Brevis (Great Toe) and Adductor Pollicis (Thumb) Muscles — 180.0; 180.0 seconds
Phase 3 N=266 Cantharidin Application in Molluscum Patients-1
Molluscum Contagiosum
Primary: Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 84 Visit (EOS) — 74; 19 Participants — p=<0.0001